KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Current Assets: 2010-2025

Historic Current Assets for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to $281.4 million.

  • Nektar Therapeutics' Current Assets fell 1.79% to $281.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.4 million, marking a year-over-year decrease of 1.79%. This contributed to the annual value of $261.3 million for FY2024, which is 20.99% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Current Assets of $281.4 million as of Q3 2025, which was up 50.81% from $186.6 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Current Assets ranged from a high of $1.1 billion in Q1 2021 and a low of $186.6 million during Q2 2025.
  • Its 3-year average for Current Assets is $320.2 million, with a median of $295.2 million in 2024.
  • Data for Nektar Therapeutics' Current Assets shows a maximum YoY crashed of 39.43% (in 2023) over the last 5 years.
  • Over the past 5 years, Nektar Therapeutics' Current Assets (Quarterly) stood at $795.6 million in 2021, then plummeted by 31.37% to $546.0 million in 2022, then tumbled by 39.43% to $330.7 million in 2023, then decreased by 20.99% to $261.3 million in 2024, then declined by 1.79% to $281.4 million in 2025.
  • Its last three reported values are $281.4 million in Q3 2025, $186.6 million for Q2 2025, and $229.9 million during Q1 2025.